PD-L1 (6C8) Monoclonal Antibody
- Size: 100ul
- Application: WB, FCM
- Reactivity: Human
- Predicted Reactivity:
-
Datasheet
Tech Support
IMAGES
Flow cytometric analysis of 293F cells expressing PD-L1 probed with PD-L1 (6C8) Monoclonal Antibody, unconjugated (bsm-58003R) at 1:100 dilution (red), compared control IgG staining (blue).
Lane 1: full-length PD-L1 transfected 293T; Lane 2: untransfected 293T, probed with PD-L1 (6C8) Monoclonal Antibody, Unconjugated (bsm-58003R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37°C.
PRODUCT DETAILS
SPECIFICATIONS |
|
|---|---|
|
PRODUCT NAME |
PD-L1 (6C8) Monoclonal Antibody |
|
CONJUGATION |
Unconjugated |
|
HOST |
Rabbit |
| SOURCE |
Recombinant human PD-L1 extracellular domain |
| IMMUNOGEN RANGE |
|
| CLONALITY |
Monoclonal |
| ISOTYPE |
IgG |
| CONCENTRATION |
Not Determined |
| PURIFICATION |
Purified by Protein A. |
| STORAGE BUFFER |
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. |
| STORAGE CONDITION |
Store for 1 year at -20°C from date of shipment. Store for 1 year at -20°C from date of shipment. |
TARGET |
|
|---|---|
| GENE ID |
|
| SUBCELLULAR LOCATION |
|
| SYNONYMS |
Programmed cell death 1 ligand 1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1; Programmed death ligand 1 |
| BACKGROUND |
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). |
| APPLICATION DILUTION |
WB(1:300-1000), FCM(1:20-100) |